← Back
NeuroTrials.ai
Neurology Clinical Trial Database

Wiebe Surgery for TLE

A Randomized, Controlled Trial of Surgery for Temporal-Lobe Epilepsy

Year of Publication: 2001

Authors: Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group

Journal: New England Journal of Medicine

Citation: Wiebe S et al. N Engl J Med. 2001;345(5):311-318. DOI: 10.1056/NEJM200108023450501

Link: https://www.nejm.org/doi/10.1056/NEJM200108023450501

PDF: https://www.nejm.org/doi/pdf/10.1056/NEJM200108023450501


Clinical Question

Is anterior temporal lobectomy superior to optimized medical therapy for achieving seizure freedom in patients with drug-resistant temporal lobe epilepsy?

Bottom Line

In this first-ever RCT of epilepsy surgery, anterior temporal lobectomy was overwhelmingly superior to medical therapy, with 58% vs 8% achieving freedom from seizures impairing awareness at 1 year (p<0.001, NNT=2). Surgery also significantly improved quality of life, disability scores, and complete seizure freedom (38% vs 3%). Surgical complications occurred in 10% (verbal memory decline, visual field cut, wound infection) with no operative mortality.

Major Points

  • Surgery superior: seizure-free at 1 year 58% vs 8% (P<0.001). NNT=2.
  • Quality of life (QOLIE-89) significantly better: surgery 75.7 vs medical 65.2 (P<0.001).
  • 80 patients randomized (40 surgery, 40 medical). Single center (London, Canada).
  • Surgery: anterior temporal lobectomy (standardized). Medical: optimized AED management.
  • Verbal memory decline in dominant surgery: 20% had significant decline on neuropsych testing.
  • 4 surgical complications: 1 wound infection, 1 CSF leak, 1 visual field defect, 1 depression.
  • Only RCT of epilepsy surgery vs medical management — remains definitive evidence.
  • Landmark trial establishing Class I evidence for surgery in drug-resistant TLE.
  • Published NEJM 2001. Led to guideline recommendations for early surgical referral.
  • Mean duration of epilepsy: ~20 years — argues for earlier referral than current practice.

Design

Study Type: Prospective, randomized, controlled, parallel-group trial with blinded outcome assessment

Randomization: 1

Blinding: Outcome assessors blinded; patients and surgeons unblinded

Enrollment Period: March 1996 to February 2000

Follow-up Duration: 1 year

Centers: 1

Countries: Canada

Sample Size: 80

Analysis: Intention-to-treat; London Health Sciences Centre, University of Western Ontario


Inclusion Criteria

  • Age 16-69 years.
  • Drug-resistant temporal lobe epilepsy (failed ≥2 adequate AED trials).
  • Seizures >1 year duration.
  • Concordant EEG and MRI findings localizing to temporal lobe.
  • Candidate for anterior temporal lobectomy.

Exclusion Criteria

  • Extratemporal epilepsy.
  • Prior resective epilepsy surgery.
  • Progressive neurological disease.
  • Contraindication to surgery.

Baseline Characteristics

CharacteristicSurgeryMedical Therapy
N4040
Mean age~35 years~35 years
MRI findingMajority mesial temporal sclerosisMajority mesial temporal sclerosis
Mean epilepsy duration~20 years~20 years

Arms

FieldAnterior Temporal LobectomyControl
InterventionStandardized anterior temporal lobectomy performed by a single surgical team within study protocolAED therapy optimized by treating epileptologists for 1 year; after 1 year, patients offered surgical evaluation/surgery
Duration1 year follow-up1 year follow-up

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Freedom from seizures impairing awareness at 1 yearPrimaryMedical: 3/40 (8%) seizure-freeSurgery: 23/40 (58%) seizure-free2<0.001
Secondary
Secondary
Secondary
Secondary
Any surgical complicationAdverseN/A4/40 (10%)
Verbal memory declineAdverseN/AReported in surgical group
Superior quadrantanopiaAdverseN/AReported in surgical group
Wound infection/CSF leakAdverseN/AReported in surgical group

Subgroup Analysis

Benefit consistent across MRI-positive (mesial temporal sclerosis) and MRI-negative cases, though numbers small


Criticisms

  • Single-center study: may not generalize to all surgical centers and teams
  • Short follow-up (1 year only): does not capture long-term seizure recurrence (30-50% by 10 years in observational data)
  • Small sample size (n=80) limits power for subgroup analyses
  • Waiting-list control design: medical group knew they would receive surgery later, potential nocebo effect
  • Cannot blind patients or surgeons: expectation bias possible
  • Predominantly mesial temporal sclerosis population -- may not generalize to other TLE pathologies
  • Limited ethnic and socioeconomic diversity

Funding

Canadian Institutes of Health Research (formerly Medical Research Council of Canada) and Ontario Ministry of Health (non-industry)

Based on: Wiebe Surgery for TLE (New England Journal of Medicine, 2001)

Authors: Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group

Citation: Wiebe S et al. N Engl J Med. 2001;345(5):311-318. DOI: 10.1056/NEJM200108023450501

Content summarized and formatted by NeuroTrials.ai.